Lindsay Androski
CIK: 0001936604
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Oct 1, 2026ABUS
Arbutus Biopharma Corp
Disposition(D)Direct24.7K shares at avg. $5.00$123K - Sep 18, 2026ABUS
Arbutus Biopharma Corp
Exercise(M)Direct116.4K shares at avg. $3.20$373K - Sep 18, 2026ABUS
Arbutus Biopharma Corp
Tax Payment(F)Direct82.5K shares at avg. $5.07$418K - Sep 18, 2026ABUS
Arbutus Biopharma Corp
Exercise(M)Direct10.5K shares at avg. $4.39$46K - Feb 2, 2026ABUS
Arbutus Biopharma Corp
Award(A)Direct28K shares- - Mar 18, 2025ABUS
Arbutus Biopharma Corp
Award(A)DirectStock Option (Right to Buy)
310.4K shares- - Jan 24, 2025ELOX
Eloxx Pharmaceuticals, Inc.
Exercise(M)Direct3.8K shares- - Oct 16, 2024ELOX
Eloxx Pharmaceuticals, Inc.
Award(A)Direct12K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 |  ABUS Arbutus Biopharma Corp | Disposition(D) | 24,655 | $5.00 | $123,275 | Direct |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | Exercise(M) | 116,408 | $3.20 | $372,506 | Direct |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | Tax Payment(F) | 82,527 | $5.07 | $418,412 | Direct |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | Exercise(M) | 10,456 | $4.39 | $45,902 | Direct |
| Feb 2, 2026 | ABUS Arbutus Biopharma Corp | Award(A) | 28,000 | - | $0 | Direct |
| Mar 18, 2025 | ABUS Arbutus Biopharma Corp | Award(A) Stock Option (Right to Buy) | 310,422 | - | - | Direct |
| Jan 24, 2025 |  ELOX Eloxx Pharmaceuticals, Inc. | Exercise(M) | 3,750 | - | $0 | Direct |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | Award(A) | 12,000 | - | $0 | Direct |
1-8 of 8 transactions
About Androski Lindsay
Androski Lindsay (SEC CIK 0001936604) files insider reports with the SEC as President and CEO of Arbutus Biopharma Corp (ABUS) and Director of Eloxx Pharmaceuticals, Inc. (ELOX).
Signal8 holds 7 ownership filings by Androski Lindsay (1 Form 3, 6 Form 4), filed between Oct 17, 2024 and Oct 7, 2026. Those filings report 8 transactions, from Oct 16, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Androski Lindsay's filings is in WARMINSTER, PA.
Recent filings by Androski Lindsay
- Oct 1, 2026: Disposition to issuer transaction of ABUS shares (Form 4, code D).
- Sep 18, 2026: Option exercise of ABUS shares (Form 4, code M).
- Sep 18, 2026: Tax withholding of ABUS shares (Form 4, code F).
- Sep 18, 2026: Option exercise of ABUS shares (Form 4, code M).
- Feb 2, 2026: Grant or award of ABUS shares (Form 4, code A).
Other insiders filing for Arbutus Biopharma Corp (ABUS)
- Beardsley Robert A, Director
- Nguyen Tuan, Chief Financial Officer
- Sawhney Roger, Director
- Hasija Anuj, Director
- Bishop Joseph E, Director
- Gline Matthew, Director